RxDoctor Payments Data

Swati Jadhav, MD

Family Medicine · Round Rock, TXNPI 1215943584

Payments from drug & device makers

$781in general payments, 2019–2025

Across 36 payments — averaging $21.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$233
  • Welch Allyn$186
  • Pfizer$154
  • AstraZeneca$116
  • Boston Scientific$30
  • Amgen$19
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$59576%
  • Other$18624%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$781 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$117,429
Medicare patients
280
Services billed
2,969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide233$287,841
JardianceEmpagliflozin72$96,611
JanuviaSitagliptin Phosphate49$51,626
MounjaroTirzepatide47$47,725
EliquisApixaban43$36,803
FarxigaDapagliflozin Propanediol37$35,190
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$23,605
TrulicityDulaglutide18$23,321
MyrbetriqMirabegron18$18,599
LinzessLinaclotide12$10,807
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$6,388
Levothyroxine Sodium511$5,353
SynthroidLevothyroxine Sodium62$5,214
Atorvastatin Calcium675$4,781
SymbicortBudesonide/Formoterol Fumarate12$4,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$287,841233 claims
Lilly USA, LLCMounjaro, Trulicity$15$71,04665 claims
AstraZenecaFarxiga, Symbicort$116$39,97049 claims
PfizerEliquis$154$36,80343 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →